Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (201-210 of 361) with videos related to

Pageof 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trialRoy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 13, 2018
DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate CancerEric Lu, George V Thomas, Yiyi Chen, et al.
Cancer|October 16, 2004
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480Tim A Ahles, James E Herndon, Eric J Small, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate CancerIvan de Kouchkovsky, Arpit Rao, Benedito A Carneiro, et al.
Prostate Cancer and Prostatic Diseases|November 3, 2018
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy seriesJames L Mohler, Susan Halabi, Stephen T Ryan, et al.
Journal of the National Cancer Institute|September 27, 2014
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancerLawrence Fong, Peter Carroll, Vivian Weinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2004
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancerWilliam K Oh, Philip W Kantoff, Vivian Weinberg, et al.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.
European Urology|October 24, 2019
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate CancerMelissa A Reimers, Steven M Yip, Li Zhang, et al.
Pageof 37

Showing results (201-210 of 361) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trialRoy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 13, 2018
DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate CancerEric Lu, George V Thomas, Yiyi Chen, et al.
Cancer|October 16, 2004
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480Tim A Ahles, James E Herndon, Eric J Small, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate CancerIvan de Kouchkovsky, Arpit Rao, Benedito A Carneiro, et al.
Prostate Cancer and Prostatic Diseases|November 3, 2018
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy seriesJames L Mohler, Susan Halabi, Stephen T Ryan, et al.
Journal of the National Cancer Institute|September 27, 2014
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancerLawrence Fong, Peter Carroll, Vivian Weinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2004
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancerWilliam K Oh, Philip W Kantoff, Vivian Weinberg, et al.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.
European Urology|October 24, 2019
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate CancerMelissa A Reimers, Steven M Yip, Li Zhang, et al.
Pageof 37